ST. LOUIS, July 28 /PRNewswire/ -- Kereos, a biotechnology company
developing targeted therapeutics and molecular imaging agents for the
treatment and detection of cancer and cardiovascular disease, announced today
that it has been selected as one of the "Fierce 15" for 2004 by FierceBiotech,
an internationally-recognized publication for the biotech industry. Kereos
was chosen as one of the top emerging biotechnology companies from more than
500 privately held firms for the company's vision, management expertise, and
overall potential to change the way disease is treated.
"Kereos' development of nanotechnology-based targeted therapeutics and
imaging agents could result in the earlier detection and more targeted
treatment of two leading killers of Americans -- cardiovascular disease and
cancer," said John Carroll, editor of FierceBiotech. "The Fierce 15
celebrates the spirit of innovation and aggressive development of new
products, and we are pleased to honor those biotechnology companies with great
potential to change the landscape of biotechnology."
"We believe that our cancer products will enable physicians to find tumors
earlier and treat them more effectively, while our lead cardiovascular
products should be the first to find and treat the unstable plaque underlying
most heart attacks," said Robert "Al" Beardsley, Ph.D., CEO of Kereos.
"Kereos is honored to be chosen from among so many outstanding companies in
our industry, and to be recognized for that vision and for the experienced
team of professionals dedicated to realizing it."
The Fierce 15 roster of winners is available in today's issue of
FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
Kereos develops products designed to provide more effective treatment and
detection of cancer and cardiovascular disease, the first of which is expected
to enter clinical trials in 2005. In addition to advancing its pipeline of
therapeutic and imaging candidates independently, Kereos is committed to
partnering with leading pharmaceutical and imaging companies. To date, it has
formed collaborations with Bristol-Myers Squibb Medical Imaging for the
development and commercialization of cardiovascular disease magnetic resonance
imaging (MRI) agents and with Philips Medical Systems for the development of
molecular imaging systems. For more information, visit Kereos' website at
FierceBiotech is an internationally recognized email newsletter for the
biotech industry. Every business day, more than 31,000 executives in over
100 countries rely on FierceBiotech for a quick, authoritative briefing on the
day's top stories. It is published by FierceMarkets, Inc. a business
publishing company based in Washington D.C.